USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: GENVEC, INC.
City: GAITHERSBURG
State: MD
Zip+4: -
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $7,210,655.00 20
SBIR Phase II $3,679,470.00 3
STTR Phase I $138,575.00 1

Award List:

Evaluation of Adenovirus Vectors in the Eye

Award Year / Program / Phase: 2003 / SBIR / Phase I
Agency: HHS
Principal Investigator: Joseph T. Bruder
Award Amount: $99,999.00
Abstract:
DESCRIPTION (provided by applicant): This proposal is designed to test an improved gene delivery strategy for the treatment of age-related macular degeneration (AMD). Wet AMD and diabetic retinopathy are the most common causes of blindness in the developed world. Both diseases are caused by the… More

Protein Production of PEDF-Potent Antiangiogenic Agent

Award Year / Program / Phase: 2003 / SBIR / Phase I
Agency: HHS
Principal Investigator: Lisa L. Wei
Award Amount: $99,876.00
Abstract:
DESCRIPTION (provided by applicant): Exudative age-related macular degeneration (AMD) and proliferative diabetic retinopathy (DR), due to aberrant choroidal and retinal neovascularization respectively, are two of the leading major causes of blindness in the US. PEDF (Pigment Epithelium-Derived… More

Development of PEDF Protein: An Antiangiogenic Agent

Award Year / Program / Phase: 2004 / SBIR / Phase II
Agency: HHS
Principal Investigator: Lisa L. Wei
Award Amount: $775,784.00
Abstract:
The leading major causes of blindness in the U.S. are exudative age-related macular degeneration (AMD) and proliferative diabetic retinopathy (DR). Both are due to aberrant neovascularization in the eye. PEDF (Pigment Epithelium-Derived Factor) is a potent endogenous antiangiogenic/neurotrophic… More

Activation of the Immune System by TNFerade

Award Year / Program / Phase: 2004 / SBIR / Phase I
Agency: HHS
Principal Investigator: Charles R. King
Award Amount: $99,544.00
Abstract:
DESCRIPTION (provided by applicant): This proposal will investigate the mechanism of action of TNFerade, a promising cancer treatment now in clinical testing. In TNFerade, the TNF coding sequence is controlled by a radiation responsive promoter, egr-1, is contained within an adenovirus vector.… More

Development of a Highly Tumor-Specific Adenovirus Vector

Award Year / Program / Phase: 2004 / SBIR / Phase I
Agency: HHS
Principal Investigator: David A. Einfeld
Award Amount: $96,739.00
Abstract:
DESCRIPTION (provided by applicant): Despite a number of newly approved drugs, cancer is responsible for over 20% of all deaths and will soon overtake heart disease as the main killer in the Western world. First generation adenovirus vectors have shown promise in the treatment of locally advanced… More

Alternate Delivery of Potent Antiangiogenic Agent-AdPEDF

Award Year / Program / Phase: 2004 / SBIR / Phase I
Agency: HHS
Principal Investigator: Lisa L. Wei
Award Amount: $139,924.00
Abstract:
DESCRIPTION (provided by applicant) Exudative age-related macular degeneration (AMD) and proliferative diabetic retinopathy (DR), due to aberrant choroidal and retinal neovascularization respectively, are two of the leading major causes of blindness in the US. PEDF (Pigment Epithelium-Derived… More

Targeting Adenovirus Vectors to Ovarian Cancer

Award Year / Program / Phase: 2004 / SBIR / Phase I
Agency: HHS
Principal Investigator: C. R. King
Award Amount: $356,058.00
Abstract:
DESCRIPTION (provided by applicant): Despite significant improvements in the management of ovarian cancer, approximately 13,900 women per year in the United States are expected to ultimately fail standard therapies and die. Peritoneal spread is the major route of dissemination and leads to… More

Targeted, Alternate Serotype Vector for Ovarian Cancer

Award Year / Program / Phase: 2004 / SBIR / Phase I
Agency: HHS
Principal Investigator: C. R. King
Award Amount: $478,188.00
Abstract:
DESCRIPTION (provided by applicant): Despite significant improvements in the management of ovarian cancer, approximately 13,900 women per year in the United States are expected to ultimately fail standard therapies and die. For the treatment of ovarian cancer, the broadly used adenovirus type 5… More

Evaluation of High-Capacity Adenovectors in the Eye

Award Year / Program / Phase: 2005 / SBIR / Phase II
Agency: HHS
Principal Investigator: Joseph T. Bruder
Award Amount: $432,726.00
Abstract:
DESCRIPTION (provided by applicant): Exudative age-related macular degeneration (AMD) is due to aberrant neovascularization in the eye, and is one of the leading major causes of blindness in the U.S. Pigment Epithelium-Derived Factor (PEDF) is a potent angiogenic and neurotrophic factor and is a key… More

High Throughput Genomics Screening for Malaria Antigen Discovery

Award Year / Program / Phase: 2005 / SBIR / Phase I
Agency / Branch: DOD / ARMY
Principal Investigator: Joseph Bruder, Director, Vaccines and Vector Progr
Award Amount: $69,993.00
Abstract:
Malaria is a major threat to world health and the personnel of the US armed forces. To date there is no available effective protective vaccine. However, an abundance of data in animal models and in humans has indicated the existence of protective antigens and demonstrated that an effective vaccine… More

Restoration of vestibular hair cells induced by AdMath1

Award Year / Program / Phase: 2005 / STTR / Phase I
Agency: HHS
Research Institution: UNIVERSITY OF KANSAS
Principal Investigator: Douglas E. Brough
Award Amount: $138,575.00
RI Contact: N/A
Abstract:
Loss of vestibular hair cells can occur due to a variety of disorders and results in dysfunction of the vestibulo-occular reflex and loss of balance. Bilateral vestibular hypofunction due to aminoglycoside ototoxicity and other means is a devastating and currently untreatable chronic disorder… More

Production of Adenovector Based Vaccines

Award Year / Program / Phase: 2005 / SBIR / Phase I
Agency: HHS
Principal Investigator: Duncan L. Mcvey
Award Amount: $598,088.00
Abstract:
DESCRIPTION (provided by applicant): Adenovirus vectors (AdVectors) designed to express an antigenic gene have shown great promise as vaccines. Although GenVec and other groups have constructed numerous AdVectors expressing a variety of antigens a substantial subset of antigen genes have been found… More

Novel Adenovirus Vectors for Biodefense Vaccines

Award Year / Program / Phase: 2006 / SBIR / Phase I
Agency: HHS
Principal Investigator: C. R. King
Award Amount: $433,476.00
Abstract:
DESCRIPTION (provided by applicant): This proposal is designed to create technology that can be rapidly applied to the generation of novel vaccines against biodefense threat agents. Antigens that have the potential to provide protection against a biodefense threats have been identified or are… More

Alternate Adenovector in Eye Gives Longer Expression

Award Year / Program / Phase: 2007 / SBIR / Phase I
Agency: HHS
Principal Investigator: Lisa L. Wei
Award Amount: $215,160.00
Abstract:
DESCRIPTION (provided by applicant): The goal of this application is to test the feasibility of a concept for improved treatment for ocular neovascular disease. The proposed strategy builds on the success of FDA approved agents that block Vascular Endothel ial Growth Factor, VEGF, but are less than… More

Preclinical Testing of an Adenoviral Vector based HSV-2 Vaccine

Award Year / Program / Phase: 2008 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $600,000.00
Abstract:
DESCRIPTION (provided by applicant): This proposal will leverage the expertise in HSV-2 and cellular immunology developed at the UW/FHCRC with the state of the art adenovirus delivery platform developed by GenVec to develop an HSV-2, adenovirus vector base d vaccine. This phase 1 SBIR application… More

Adenovirus Vectors for Respiratory Syncytial Virus Vaccination

Award Year / Program / Phase: 2008 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $600,000.00
Abstract:
DESCRIPTION (provided by applicant): Respiratory syncytial virus (RSV) is the leading viral cause of lower respiratory illness and hospitalization in young children and has long been recognized as a priority disease for a vaccine. RSV presents many challen ges for vaccine efficacy. Over the nearly… More

Novel Ad5 Malaria Vaccine That Circumvents Pre-existing Ad5 Immunity

Award Year / Program / Phase: 2008 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $599,549.00
Abstract:
DESCRIPTION (provided by applicant): Malaria is the most devastating parasitic disease affecting humans. Each year, there are 350-500 million clinical cases and greater than one million deaths due to malaria, primarily of children in sub-Saharan Africa. There is an urgent need for a safe and… More

Development of an Ad14 Vaccine

Award Year / Program / Phase: 2009 / SBIR / Phase I
Agency: HHS
Principal Investigator: Jason Gall
Award Amount: $500,313.00
Abstract:
DESCRIPTION (provided by applicant): Recent reports indicate that a new strain of adenovirus serotype 14 (Ad14) is causing frequent acute respiratory disease (ARD) and deaths in otherwise health people. The overall goal of this SBIR is to generate a vaccin e that can protect against Ad14 infection… More

Development of Novel Alternative Serotype Adenoviral Vectors for Gene Delivery in

Award Year / Program / Phase: 2009 / SBIR / Phase I
Agency: HHS
Principal Investigator: Douglas E. Brough
Award Amount: $138,699.00
Abstract:
DESCRIPTION (provided by applicant): Myriad studies have examined the potential of gene therapy in the inner ear. For the most part they have focused on adenoviral vectors and delivery into the cochlea. Most studies have emphasized looking at expression o f marker genes driven by a CMV promoter and… More

Production of Adenovector Based Vaccines

Award Year / Program / Phase: 2009 / SBIR / Phase II
Agency: HHS
Principal Investigator: Duncan L. Mcvey
Award Amount: $2,470,960.00
Abstract:
DESCRIPTION (provided by applicant): Adenovirus vectors (Advectors) designed to express an antigenic gene have shown great promise as vaccines. Although GenVec and other groups have constructed numerous Advectors expressing a variety of antigens a substant ial subset of antigen genes have been found… More

Local Therapy-A Novel Approach to Cancer Metastases

Award Year / Program / Phase: 2009 / SBIR / Phase I
Agency: HHS
Principal Investigator: Lisa L. Wei
Award Amount: $295,991.00
Abstract:
DESCRIPTION (provided by applicant): Metastases are the leading cause of death of most cancer patients. Leveraging the immune system to eliminate micrometastasis has long been attempted with only modest success. One limitation is that the local tumor envir onment often forms immune barriers that… More

High Throughput Genomics Screening for Malaria Antigen Discovery

Award Year / Program / Phase: 2009 / SBIR / Phase I
Agency: HHS
Principal Investigator: Joseph T. Bruder
Award Amount: $600,000.00
Abstract:
DESCRIPTION (provided by applicant): Malaria is a major threat to world health. Each year, there are 350-500 million clinical cases and greater than one million deaths due to malaria, primarily of children in sub- Saharan Africa. There is an urgent need fo r a safe and effective malaria vaccine and… More

Adenovirus-vectored RSV vaccine not inhibited by maternal immunity

Award Year / Program / Phase: 2012 / SBIR / Phase I
Agency: HHS
Principal Investigator: Jason Gall – 240-632-5547
Award Amount: $589,058.00
Abstract:
DESCRIPTION (provided by applicant): RSV is the leading viral cause of lower respiratory illness and hospitalization in young children, yet there isn't an approved vaccine. The vast majority of children infected with RSV suffer from a mild upper respiratory tract infection; however, severe… More

Pre-erythrocytic Stage Antigen Discovery for Malaria Vaccine Development

Award Year / Program / Phase: 2012 / SBIR / Phase I
Agency: HHS
Principal Investigator: Joseph T. Bruder – 240-632-5543
Award Amount: $600,000.00
Abstract:
DESCRIPTION (provided by applicant): The development of an effective malaria vaccine is a high global health priority. Malaria is the most burdensome parasitic disease of man, exacting an estimated toll of 863,000 deaths and 243 million clinical cases peryear. There is an urgent need for a safe and… More